Murumägi, Astrid http://orcid.org/0000-0002-7797-188X
Ungureanu, Daniela
Khan, Suleiman
Arjama, Mariliina
Välimäki, Katja
Ianevski, Aleksandr
Ianevski, Philipp
Bergström, Rebecka
Dini, Alice http://orcid.org/0000-0002-2720-4551
Kanerva, Anna
Koivisto-Korander, Riitta
Tapper, Johanna
Lassus, Heini http://orcid.org/0000-0003-0598-5147
Loukovaara, Mikko
Mägi, Andrus
Hirasawa, Akira
Aoki, Daisuke
Pietiäinen, Vilja http://orcid.org/0000-0003-3125-2406
Pellinen, Teijo http://orcid.org/0000-0001-9652-7373
Bützow, Ralf http://orcid.org/0000-0003-4366-5099
Aittokallio, Tero http://orcid.org/0000-0002-0886-9769
Kallioniemi, Olli
Funding for this research was provided by:
Academy of Finland (333583, 278741, 279163, 292611, 310507, 296516, 313267, 326238)
Syöpäsäätiö
Syöpäjärjestöt
Article History
Received: 13 April 2022
Revised: 9 November 2022
Accepted: 11 November 2022
First Online: 7 December 2022
Competing interests
: OK is a co-founder and a board member of Medisapiens and Sartar Therapeutics and has received royalty on patents licensed by Vysis-Abbot. His research group has a Vinnova-funded collaborative programme with Astra-Zeneca, Labcyte, Takara Biosciences and Pelago. VP has received a grant from UPM-Kymmene. Other authors did not disclose any potential conflicts of interest.
: The study was approved by the Ethics Committee of the Helsinki University Hospital and performed in accordance with the Declaration of Helsinki. All patient material and clinical data were obtained upon informed consent.
: Not applicable.